Technical Analysis for MBIO - Mustang Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 2.94% | |
| Outside Day | Range Expansion | 2.94% | |
| Wide Bands | Range Expansion | 2.94% | |
| Narrow Range Bar | Range Contraction | 6.39% | |
| Earnings Movers | Other | 6.39% | |
| Inside Day | Range Contraction | 6.39% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| 10 DMA Resistance | about 18 hours ago |
| Up 3% | about 21 hours ago |
| Up 2% | about 21 hours ago |
| Up 1% | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
Mustang Bio, Inc. Description
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Virotherapy Gene Therapy Cancer Cell Epidermal Growth Factor Receptor T Cell Chimeric Antigen Receptor Immunotherapy Products Cancer Immunotherapy Product Cellectis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.17 |
| 52 Week Low | 0.22 |
| Average Volume | 305,545 |
| 200-Day Moving Average | 1.66 |
| 50-Day Moving Average | 0.66 |
| 20-Day Moving Average | 0.30 |
| 10-Day Moving Average | 0.28 |
| Average True Range | 0.05 |
| RSI (14) | 30.07 |
| ADX | 43.12 |
| +DI | 11.85 |
| -DI | 30.38 |
| Chandelier Exit (Long, 3 ATRs) | 0.29 |
| Chandelier Exit (Short, 3 ATRs) | 0.38 |
| Upper Bollinger Bands | 0.38 |
| Lower Bollinger Band | 0.22 |
| Percent B (%b) | 0.36 |
| BandWidth | 53.34 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.13 |
| MACD Histogram | 0.0248 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.30 | ||||
| Resistance 3 (R3) | 0.30 | 0.29 | 0.30 | ||
| Resistance 2 (R2) | 0.29 | 0.29 | 0.29 | 0.30 | |
| Resistance 1 (R1) | 0.28 | 0.28 | 0.28 | 0.29 | 0.29 |
| Pivot Point | 0.27 | 0.27 | 0.27 | 0.28 | 0.27 |
| Support 1 (S1) | 0.27 | 0.27 | 0.26 | 0.27 | 0.26 |
| Support 2 (S2) | 0.26 | 0.26 | 0.26 | 0.26 | |
| Support 3 (S3) | 0.25 | 0.26 | 0.26 | ||
| Support 4 (S4) | 0.25 |
